- Home
- MQY vs PSNL Comparison
MQY vs PSNL Comparison
Compare MQY & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MQY | PSNL |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.1M | 729.1M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MQY | PSNL |
|---|---|---|
| Price | $11.36 | $6.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 331.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $16.94 |
| Revenue Next Year | N/A | $36.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.52 | $2.83 |
| 52 Week High | $11.97 | $11.50 |
Technical Indicators
Market Signals| Indicator | MQY | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 28.35 | 34.61 |
| Support Level | $11.17 | $4.31 |
| Resistance Level | $11.44 | $6.94 |
| Average True Range (ATR) | 0.10 | 0.71 |
| MACD | -0.05 | -0.19 |
| Stochastic Oscillator | 6.30 | 5.95 |
Price Performance
Historical ComparisonAbout MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.